 The efficacy of Xolair has been investigated in a series of clinical trials which included two pivotal phase III placebo-controlled trials in over 1,000 allergic asthma patients. |
 Xolair works by binding to free immunoglobulin E (IgE) in the blood to prevent mast cell degranulation and the release of pharmacologically active substances that are the hallmark of the early allergic inflammatory process. (Source: ABPI) |
 It is believed that Xolair will be first marketed as maintenance therapy for the prophylaxis of asthma exacerbations and control of asthma symptoms. |
 COPD is a progressive disorder of the lungs characterised by airflow obstruction. |
 Drugs which address the underlying tissue damage in COPD and prevent the progressive decline in lung function which is a hallmark of this disease are urgently needed. |
 Ariflo (cilomilast) is an oral selective phosphodiesterase (PDE) IV inhibitor. |
 Diagram of the heart showing the major arteries, veins, valves and the direction of blood flow. Deoxygenated blood is shown in purple and oxygenated blood in red. |
 Summary of major and minor diagnostic criteria for CHF derived from the Framingham Heart Study. |
 CHF is a progressive disease, which if left untreated leads inexorably to acute heart failure and potentially death. |
 Triggering a heartbeat. Calcium floods into heart cells through the calcium channel at each beat, which releases internal stored calcium (blue arrows). This causes the muscle to contract. Three calcium channel blockers act at different sites in this calcium channel. There are also sodium-potassium channels where digoxin acts and a separate sodium-calcium exchange channel. |
||
| Copyright Notice: Copyright for all images on this web site is held by the individual companies providing material for the site. Click on the image concerned to be taken through to the project, containing information on the company involved. | ||
Copyright 2008 SPG Media Limited a subsidiary of SPG Media Group PLC
